# In Silico Exploration of CD200 as a Therapeutic Target for COVID-19

## TL;DR

This study explores CD200 as a potential new target for treating COVID-19 by analyzing virus-host interactions using a computational method.

## Contribution

The study identifies CD200 as a novel therapeutic target for COVID-19 using the informational spectrum method.

## Key findings

- A highly conserved region of the SARS-CoV-2 spike protein was identified as a potential drug and vaccine target.
- CD200 (OX-2 membrane glycoprotein) was found to interact with the spike protein and could be a new therapeutic target.
- The findings suggest potential broad effectiveness against all circulating SARS-CoV-2 variants.

## Abstract

SARS-CoV-2, the pathogen causing COVID-19, continues to pose a significant threat to public health and has had major economic implications. Developing safe and effective vaccines and therapies offers a path forward for overcoming the COVID-19 pandemic. The presented study, performed by using the informational spectrum method (ISM), representing an electronic biology-based tool for analysis of protein–protein interactions, identified the highly conserved region of spike protein (SP) from SARS-CoV-2 virus, which is essential for recognition and targeting between the virus and its protein interactors on the target cells. This domain is suggested as a promising target for the drug therapy and vaccines, which could be effective against all currently circulating variants of SARS-CoV-2 viruses. The analysis of the virus/host interaction, performed by the ISM, also revealed OX-2 membrane glycoprotein (CD200) as a possible interactor of SP, which could serve as a novel therapeutic target for COVID-19 disease.